• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Parker Geoffrey M. bought $683 worth of shares (190 units at $3.60), increasing direct ownership by 0.02% to 819,590 units (SEC Form 4)

    3/6/24 9:52:06 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Parker Geoffrey M.

    (Last) (First) (Middle)
    210 EAST GRAND AVE

    (Street)
    SOUTH SAN FRANCISCO 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Allogene Therapeutics, Inc. [ ALLO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CHIEF FINANCIAL OFFICER
    3. Date of Earliest Transaction (Month/Day/Year)
    01/30/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 01/30/2024 P 190(1) A $3.595 819,590 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Mr. Parker was notified by his broker on March 4, 2024 that these shares were purchased in an account held by the Geoffrey M. Parker and Jill G. Parker Rev. Trust dated January 27, 2000 for which Mr. Parker does not have discretion. This account is intended to closely track the performance of the Russell 2000 and is frequently rebalanced by an algorithm designed by the broker which led to the purchase of these shares. Restrictions have been now placed on all such accounts held by the Trust to avoid such purchases of the Issuer stock in the future.
    Remarks:
    /s/Earl Douglas, Attorney-in-Fact 03/06/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ALLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLO

    DatePrice TargetRatingAnalyst
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/14/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    8/8/2024$13.00 → $11.00Outperform
    Oppenheimer
    5/31/2024$11.00Overweight
    Piper Sandler
    1/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    1/5/2024Buy → Neutral
    Guggenheim
    12/8/2023$7.00Buy
    Citigroup
    12/8/2023Buy
    Citigroup
    More analyst ratings

    $ALLO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Belldegrun Arie was granted 344,828 shares and bought $4,999,997 worth of shares (1,724,137 units at $2.90) (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      5/20/24 9:33:32 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Parker Geoffrey M. bought $683 worth of shares (190 units at $3.60), increasing direct ownership by 0.02% to 819,590 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      3/6/24 9:52:06 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Messemer Deborah M. sold $52,377 worth of shares (36,885 units at $1.42), decreasing direct ownership by 26% to 107,431 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      6/12/25 4:18:31 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVP, Finance Yoshiyama Annie sold $13,537 worth of shares (9,601 units at $1.41), decreasing direct ownership by 7% to 130,663 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      4/23/25 5:28:51 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Chang David D sold $91,469 worth of shares (46,668 units at $1.96), decreasing direct ownership by 0.88% to 5,276,569 units (SEC Form 4)

      4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)

      3/18/25 5:30:50 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Allogene Therapeutics Inc.

      10-Q - Allogene Therapeutics, Inc. (0001737287) (Filer)

      5/13/25 4:07:36 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)

      5/13/25 4:06:51 PM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Allogene Therapeutics Inc.

      SCHEDULE 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)

      5/13/25 11:44:13 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALLO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Allogene downgraded by Citizens JMP

      Citizens JMP downgraded Allogene from Mkt Outperform to Mkt Perform

      5/14/25 8:54:15 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Allogene upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00

      3/14/25 7:12:11 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer resumed coverage on Allogene with a new price target

      Oppenheimer resumed coverage of Allogene with a rating of Outperform and set a new price target of $11.00 from $13.00 previously

      8/8/24 7:10:59 AM ET
      $ALLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care